Ethical Implications of Patient Access Restrictions
Jessica Nance, MD, MS, and Emma Ciafaloni, MD, FAAN, discuss ethical dilemmas, exploring how patient subgroup restrictions on orphan drugs can impact access and cost control.
Stay updated with breaking news from Equitable Access. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Jessica Nance, MD, MS, and Emma Ciafaloni, MD, FAAN, discuss ethical dilemmas, exploring how patient subgroup restrictions on orphan drugs can impact access and cost control.
Ryan Haumschild, PharmD, MS, MBA, leads a discussion on factors that influence coverage of non-oncology gene therapies, exploring the balance between long-term cost savings and high initial prices, patient selection, and the durability of effect for these therapies.
Experts discuss the landscape of treatment options for Duchenne muscular dystrophy, examine the benefits and risks of gene therapy and conventional steroid treatments, and emphasize the need for early intervention and comprehensive care.
I am a professional researcher. My world revolves around data: verifiable facts, concise figures, and reliable statistics. I don't make a habit of dealing in
Dr Clement Apaak, the Builsa South MP and ranking member of the Education Committee of Parliament, has endorsed Africa Education Watch’s...